Navigation Links
Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of,Blindness in Premature Infants

ersities mark an important scientific milestone in Insmed's development of IPLEX(TM) as a treatment for ROP. They suggest that IGFBP-3, once thought only to regulate IGF-I, actually plays a broader role in human development and in the growth or regeneration of human tissues. Not only is this discovery important in the fight against ROP, but it also suggests promising avenues for research into the treatment of other conditions associated with ischemia and vascular damage."

About IPLEX(TM) and ROP

IPLEX(TM) is currently in the first phase of clinical development for the treatment of ROP, a disease that affects an estimated 14,000 to 16,000 premature infants each year. ROP impedes the development of the small blood vessels in the back of the eye, leading to blindness in severe cases. A Phase I clinical study investigating IPLEX(TM) as a treatment for ROP is underway at the University of Goteborg, in collaboration with scientists at the Harvard Medical School. Ten patients will be enrolled with the objective of the study being to determine the dose of IPLEX(TM) required to increase serum IGF-I levels into the normal physiological range. This study is expected to be completed by the end of 2007.

About Insmed

Insmed is a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs. For more information, please visit www.insmed.com. To be added to Insmed's investor lists, please contact Haris Tajyar at htajyar@irintl.com or at 818-382-9702.

Forward Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed produ
'"/>




Page: 1 2 3

Related medicine technology :

1. Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference
2. Insmed Announces Promising Results From IPLEX Phase II Myotonic Muscular Dystrophy Clinical Study
3. Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
6. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
7. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
8. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
9. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
10. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
11. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
Post Your Comments:
(Date:2/27/2015)...  Acsis Inc., the market leader for supply chain ... John DiPalo , Acsis, Chief Strategy Officer, has ... Executive 2015 Provider Pro to Know. The award ... help prepare their companies, and customers, supply chains for ... list of Provider Pros to Know is featured in ...
(Date:2/27/2015)... NEW YORK , Feb. 27, 2015 ... investigating the board of Salix Pharmaceuticals, Ltd. (NASDAQ: ... only $158.00 per share. Concerned SLXP investors are encouraged ... . The investigation focuses upon the ... proposed agreement, Salix shareholders would receive only $158.00 per ...
(Date:2/27/2015)... , Feb. 27, 2015 An aggressive campaign ... cut the rate of infection with a dangerous drug-resistant ... Clostridium difficile, or C.diff, is a bacterium ... inflammation of the colon. A recent article in the ... difficile Infection in the United States ...
Breaking Medicine Technology:Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3
... Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) ... publication of an interview of its President Deborah Jenkins ... interviews with CEOs and CFOs of publicly traded growth ... by Lynn Fosse, Senior Editor, CEOCFOInterviews.com include why Ms. ...
... Conn., May 19, 2011 Boehringer Ingelheim Pharmaceuticals, ... (dabigatran etexilate mesylate) capsules has received preferred Tier ... D plans through its pharmacy benefits manager, Prescription ... AARP Medicare Rx and AARP MedicareComplete from Secure ...
Cached Medicine Technology:WNDM President Interviewed; Discusses 2011 Outlook and Beyond 2WNDM President Interviewed; Discusses 2011 Outlook and Beyond 3Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 2Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 3Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 4Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 5Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 6
(Date:2/28/2015)... February 28, 2015 Plugin creators from ... Volume 2. A fully customizable transition pack ... Volume 2 gives users total control over 30 transition ... CEO of Pixel Film Studios. “TransFold Volume 2 gives ... , TransFold Volume 2 from Pixel Film Studios brings ...
(Date:2/28/2015)... My Shiney Hiney® LLC., the renowned brand ... Las Vegas, Nevada for the annual ASD Market Week tradeshow. ... leading consumer-goods tradeshows and My Shiney Hiney will be one ... Shiney Hiney can be found at booth number C1663. , ... at-home personal hygiene brush and cleansing system exclusively created to ...
(Date:2/27/2015)... Danvers, MA (PRWEB) February 27, 2015 ... enterprise mobility management services, and one of ... today announced support for Bell Mobility within their ... suite of services. Wireless Analytics’ newly developed ... and reporting for the Canadian wireless carrier’s business ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Just a ... air for those suffering from Sjögren’s Syndrome after a ... by researchers at the University of Buffalo and Immco ... of research was to develop a new diagnostic ... the presence of new autoantibodies. Researchers aimed to develop ...
(Date:2/27/2015)... 2015 On March 2-4, the ... National Cancer Institute (NCI) will co-host the annual ... Institutes of Health (NIH), in Bethesda, Maryland. The ... to medical professionals and scientists who specialize in ... general public, including patients, their families, and caregivers. ...
Breaking Medicine News(10 mins):Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Breakthrough Blood Test for Early Detection of Sjögren’s Syndrome Now Available 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3
... ),announced today the election of Robert M. Amen, 58, to ... increases the number,of Wyeth board members from 13 to 14. ... International,Flavors & Fragrances Inc. (NYSE: IFF ) in New ... fragrances used in a wide variety of,consumer products and packaged ...
... WARSAW, Ind., Sept. 27 As part of ... DePuy,Orthopaedics, Inc. has entered into an agreement with ... reported government,investigation into sales practices in the orthopaedics ... the U.S. Attorney,s Office, District,of New Jersey. ...
... due to packaging and sound-alike drug,names, HARRISBURG, ... high (23%) in the number of reports submitted ... Patient Safety,Authority highlights the common causes of drug ... Unclear and confusing labeling and packaging as well ...
... (NEDA) Educators Seminar Thursday, October,4 in San Diego Informs Teachers, Administrators on ... ... NEW YORK, Sept. 27 Educators are in a unique,position to save ... eating disorders. For this reason, the National Eating Disorders Association will ...
... TRIANGLE PARK, N.C., Sept. 27 North Carolina,students interested in ... 2007 Contract Programs Career Conferences on,Optometry sponsored by the N.C. ... the state: -- North Carolina State University (Raleigh, NC) ... October 8, 2007 North Carolina State University in the ...
... WASHINGTON, Sept. 27 - Pharmaceutical,Research and Manufacturers of ... following statement today on the enactment of the ... "By signing into law the ,Food and Drug ... step to both strengthen our nation,s drug,safety system ...
Cached Medicine News:Health News:Statement of DePuy Orthopaedics, Inc. Regarding Agreement with U.S. Attorney's Office 2Health News:Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 2Health News:Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 3Health News:Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 4Health News:Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 5Health News:Spectrum of Eating Disorders - from Anorexia to Obesity - are Cause for Rising Concern among K-12 Students and Educators 2Health News:Optometry Career Conferences Set for Five N.C. Campuses in October 2Health News:PhRMA Statement on Enactment of FDA Legislation 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: